Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rasagiline
Drug ID BADD_D02441
Description Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Indications and Usage For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
Marketing Status approved
ATC Code N04BD02
DrugBank ID DB01367
KEGG ID D08469; D10829
MeSH ID C031967
PubChem ID 3052776
TTD Drug ID D06OMW
NDC Product Code 16714-770; 0093-3061; 67877-260; 47781-683; 42291-780; 67877-259; 16714-771; 0093-3060; 42571-221; 47781-690; 42571-220; 42291-779
UNII 003N66TS6T
Synonyms rasagiline | N-2-propynyl-1-indanamine | AGN 1135 | AGN-1135 | TVP 1022 | TVP1022 | TVP-1022 | N-propargyl-1-aminoindan mesylate | rasagiline hydrochloride | TVP 101 | TVP-101 | 2,3-dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride | Azilect
Chemical Information
Molecular Formula C12H13N
CAS Registry Number 136236-51-6
SMILES C#CCNC1CCC2=CC=CC=C12
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acute myocardial infarction24.04.04.001; 02.02.02.0010.004871%Not Available
Affective disorder19.04.04.0010.003572%Not Available
Aggression19.05.01.0010.002436%Not Available
Agitation19.06.02.001; 17.02.05.0120.006008%
Akinesia17.01.02.0030.002436%Not Available
Altered state of consciousness19.07.01.003; 17.02.04.0010.005683%Not Available
Amaurosis06.02.10.0010.001624%Not Available
Angina pectoris02.02.02.002; 24.04.04.0020.001624%
Anxiety19.06.02.0020.017211%
Aphasia19.21.01.001; 17.02.03.0010.003247%
Aspiration22.02.07.0070.003247%
Asthenia08.01.01.0010.007307%Not Available
Atrial fibrillation02.03.03.0020.007632%
Back pain15.03.04.0050.004059%
Blood pressure fluctuation24.06.01.0020.003247%Not Available
Bradykinesia17.01.02.0040.002436%Not Available
Cardiac arrest02.03.04.0010.003247%
Cardio-respiratory arrest02.03.04.002; 22.02.06.0070.001624%Not Available
Cardiovascular disorder24.03.02.009; 02.11.01.0100.001624%Not Available
Cerebral haemorrhage24.07.04.001; 17.08.01.0030.003247%Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.004059%Not Available
Cholecystitis acute09.03.01.0030.001624%Not Available
Coma17.02.09.0010.002436%Not Available
Completed suicide19.12.01.001; 08.04.01.0100.002436%Not Available
Condition aggravated08.01.03.0040.022570%Not Available
Confusional state19.13.01.001; 17.02.03.0050.005683%
Death08.04.01.0010.032474%
Decubitus ulcer23.03.11.0060.001624%Not Available
Dehydration14.05.05.0010.007307%
Delirium19.13.02.0010.002436%
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages